Intensity Therapeutics, Inc. Common stock
Stock Chart, Company Information, and Scan Results
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Intensity Therapeutics, Inc. Common stock Company Information, Fundamentals, and Technical Indicators
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Intensity Therapeutics, Inc. Common stock In Our Stock Scanner
As of Oct 20, 2025Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.